Achievement Rates of Japan Atherosclerosis Society Guidelines 2007 LDL-Cholesterol Goals with Rosuvastatin or Atorvastatin in Patients Who Had Not Achieved Their Goal with Atorvastatin

Autor: Takashi Uegaito, Hirokazu Mitsuoka, Masayasu Izuhara, Mitsuo Matsuda, Keisuke Shioji
Rok vydání: 2014
Předmět:
Male
medicine.medical_specialty
Time Factors
Atorvastatin
Coronary Artery Disease
Pharmacology
Coronary artery disease
Pharmacotherapy
Japan
Risk Factors
Internal medicine
medicine
Clinical endpoint
Humans
Pyrroles
Pharmacology (medical)
In patient
Rosuvastatin
cardiovascular diseases
Rosuvastatin Calcium
Societies
Medical
Aged
Dyslipidemias
Ldl cholesterol
Sulfonamides
Drug Substitution
business.industry
nutritional and metabolic diseases
Cholesterol
LDL
General Medicine
Middle Aged
Atherosclerosis
medicine.disease
Fluorobenzenes
Pyrimidines
Treatment Outcome
Heptanoic Acids
Practice Guidelines as Topic
Female
lipids (amino acids
peptides
and proteins)
Guideline Adherence
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiology and Cardiovascular Medicine
business
Biomarkers
Dyslipidemia
medicine.drug
Zdroj: Cardiovascular Therapeutics. 32:97-104
ISSN: 1755-5914
DOI: 10.1111/1755-5922.12066
Popis: Summary Background The Japan Atherosclerosis Society's 2007 Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases (JAS2007GL) advocate reducing LDL cholesterol (LDL-C) to target levels in patients with dyslipidemia, but achievement rates are frequently unsatisfactory even in the presence of lipid-lowering therapy. This multicenter, open-label, randomized, parallel-group study compared the efficacy of rosuvastatin and atorvastatin on JAS2007GL LDL-C goals in Japanese patients not achieving their target goal with atorvastatin treatment. Methods The study involved 20 clinical institutes in Japan (Kishiwada Atherosclerosis Prevention Study [KAPS] Group). Patients with category II or III risk of coronary artery disease (CAD), or those with a history of CAD (secondary prevention), who had not achieved their JAS2007GL LDL-C goals during treatment with atorvastatin for at least 4 weeks were switched either to rosuvastatin 5 mg/day (from atorvastatin 10 mg/day) or rosuvastatin 10 mg/day (from atorvastatin 20 mg/day) (n = 75) or continued to receive atorvastatin (n = 77). The primary endpoint was achievement of LDL-C goals at 3 months. The main secondary endpoint was achievement of LDL-C goal + high-sensitivity C-reactive protein level
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje